Clinical Specialty Index

Plasma p-tau217 Clocks Estimate Timing of Alzheimer Symptom Onset
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Moderate

This work demonstrates that a single blood-based %p-tau217 measurement can estimate not only whether but approximately when a cognitively unimpaired person will develop symptomatic Alzheimer disease, with implications for how pharmacists interpret emerging blood biomarker tests and screen for anti-amyloid therapy candidates.

Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low

This real-world diagnostic study extends plasma p-tau217 validation to early-onset Alzheimer's disease and flags severe renal impairment as a false-positive risk relevant to biomarker interpretation.

Automated Plasma p-tau217 Accurately Detects Alzheimer Pathology Across Care Settings
Analysis Neurology / Neuropharmacology Practice-changing Grade: High

This multicohort validation gives neurology pharmacists concrete accuracy, cutoff, and workflow data for a scalable blood test that can gate amyloid-targeting therapy eligibility.

Tenecteplase Boosts Late-Window Reperfusion but Not 90-Day Function
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low

Tenecteplase enhances late-window stroke reperfusion without added hemorrhage risk.

Blood Biomarker Guideline Sets Accuracy Thresholds for Alzheimer's Workup
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low

This Alzheimer's Association guideline gives pharmacists concrete sensitivity and specificity thresholds for judging whether a plasma Alzheimer's test is fit for triaging or confirmatory use in specialty memory care.

TIMELESS: Late-Window Tenecteplase Fails to Improve Stroke Outcomes
Analysis Neurology / Neuropharmacology Confirmatory Grade: High

Tenecteplase fails to outperform placebo in delayed stroke treatment.

Perfusion-Selected Alteplase Extends Thrombolysis Window to 9 Hours
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Moderate

Alteplase shows promise for late-presenting stroke when guided by imaging.

MRI Mismatch Extends Alteplase to Unknown-Onset Stroke
Analysis Neurology / Neuropharmacology Practice-changing Grade: Moderate

MRI-guided thrombolysis may benefit stroke of unknown onset.